Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

G. L. Davis, L. A. Balart, Eugene R Schiff, K. Lindsay, H. C. Bodenheimer, R. P. Perrillo, W. Carey, I. M. Jacobson, J. Payne, J. L. Dienstag, D. H. VanThiel, C. Tamburro, J. Lefkowitch, J. Albrecht, C. Meschievitz, T. J. Ortego, A. Gibas, A. Kilian, S. Bariletto

Research output: Contribution to journalArticle

1563 Citations (Scopus)

Abstract

Chronic hepatitis C (non-A, non-B hepatitis) is a common and often progressive viral liver disease. To assess the efficacy of therapy with the antiviral agent interferon alfa, we randomly assigned 166 patients with chronic hepatitis C to treatment with either 3 million or 1 million units of recombinant interferon alfa three times weekly for 24 weeks, or to no treatment. The probability of normalization or near normalization of the serum alanine aminotransferase levels after six months of interferon therapy was 46 percent in patients treated with 3 million units of interferon (p<0.001) and 28 percent in those treated with 1 million units (P<0.02), but only 8 percent in untreated patients. The serum alanine aminotransferase level became completely normal in 22 of the 26 patients (85 percent) who responded to treatment with 3 million units of interferon and 9 of the 16 patients (56 percent) who responded to treatment with 1 million units. The patients who received 3 million units of interferon had histologic improvement because of the regression of lobular and periportal inflammation. Relapse within six months after the completion of treatment occurred in 51 percent of the patients treated with 3 million units of interferon and 44 percent of those treated with 1 million units. We conclude that a 24-week course of interferon therapy is effective in controlling disease activity in many patients with hepatitis C, although relapse after the cessation of treatment is common.

Original languageEnglish
Pages (from-to)1501-1506
Number of pages6
JournalNew England Journal of Medicine
Volume321
Issue number22
StatePublished - Jan 1 1989

Fingerprint

Chronic Hepatitis C
Interferon-alpha
Randomized Controlled Trials
Interferons
Therapeutics
Alanine Transaminase
Recurrence
Withholding Treatment
Virus Diseases
Hepatitis C
Serum
Hepatitis
Antiviral Agents
Liver Diseases
Inflammation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Perrillo, R. P., ... Bariletto, S. (1989). Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. New England Journal of Medicine, 321(22), 1501-1506.

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. / Davis, G. L.; Balart, L. A.; Schiff, Eugene R; Lindsay, K.; Bodenheimer, H. C.; Perrillo, R. P.; Carey, W.; Jacobson, I. M.; Payne, J.; Dienstag, J. L.; VanThiel, D. H.; Tamburro, C.; Lefkowitch, J.; Albrecht, J.; Meschievitz, C.; Ortego, T. J.; Gibas, A.; Kilian, A.; Bariletto, S.

In: New England Journal of Medicine, Vol. 321, No. 22, 01.01.1989, p. 1501-1506.

Research output: Contribution to journalArticle

Davis, GL, Balart, LA, Schiff, ER, Lindsay, K, Bodenheimer, HC, Perrillo, RP, Carey, W, Jacobson, IM, Payne, J, Dienstag, JL, VanThiel, DH, Tamburro, C, Lefkowitch, J, Albrecht, J, Meschievitz, C, Ortego, TJ, Gibas, A, Kilian, A & Bariletto, S 1989, 'Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial', New England Journal of Medicine, vol. 321, no. 22, pp. 1501-1506.
Davis, G. L. ; Balart, L. A. ; Schiff, Eugene R ; Lindsay, K. ; Bodenheimer, H. C. ; Perrillo, R. P. ; Carey, W. ; Jacobson, I. M. ; Payne, J. ; Dienstag, J. L. ; VanThiel, D. H. ; Tamburro, C. ; Lefkowitch, J. ; Albrecht, J. ; Meschievitz, C. ; Ortego, T. J. ; Gibas, A. ; Kilian, A. ; Bariletto, S. / Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. In: New England Journal of Medicine. 1989 ; Vol. 321, No. 22. pp. 1501-1506.
@article{e9c37ec1cf9f40d495f95d6f05676a1c,
title = "Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial",
abstract = "Chronic hepatitis C (non-A, non-B hepatitis) is a common and often progressive viral liver disease. To assess the efficacy of therapy with the antiviral agent interferon alfa, we randomly assigned 166 patients with chronic hepatitis C to treatment with either 3 million or 1 million units of recombinant interferon alfa three times weekly for 24 weeks, or to no treatment. The probability of normalization or near normalization of the serum alanine aminotransferase levels after six months of interferon therapy was 46 percent in patients treated with 3 million units of interferon (p<0.001) and 28 percent in those treated with 1 million units (P<0.02), but only 8 percent in untreated patients. The serum alanine aminotransferase level became completely normal in 22 of the 26 patients (85 percent) who responded to treatment with 3 million units of interferon and 9 of the 16 patients (56 percent) who responded to treatment with 1 million units. The patients who received 3 million units of interferon had histologic improvement because of the regression of lobular and periportal inflammation. Relapse within six months after the completion of treatment occurred in 51 percent of the patients treated with 3 million units of interferon and 44 percent of those treated with 1 million units. We conclude that a 24-week course of interferon therapy is effective in controlling disease activity in many patients with hepatitis C, although relapse after the cessation of treatment is common.",
author = "Davis, {G. L.} and Balart, {L. A.} and Schiff, {Eugene R} and K. Lindsay and Bodenheimer, {H. C.} and Perrillo, {R. P.} and W. Carey and Jacobson, {I. M.} and J. Payne and Dienstag, {J. L.} and VanThiel, {D. H.} and C. Tamburro and J. Lefkowitch and J. Albrecht and C. Meschievitz and Ortego, {T. J.} and A. Gibas and A. Kilian and S. Bariletto",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "321",
pages = "1501--1506",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "22",

}

TY - JOUR

T1 - Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

AU - Davis, G. L.

AU - Balart, L. A.

AU - Schiff, Eugene R

AU - Lindsay, K.

AU - Bodenheimer, H. C.

AU - Perrillo, R. P.

AU - Carey, W.

AU - Jacobson, I. M.

AU - Payne, J.

AU - Dienstag, J. L.

AU - VanThiel, D. H.

AU - Tamburro, C.

AU - Lefkowitch, J.

AU - Albrecht, J.

AU - Meschievitz, C.

AU - Ortego, T. J.

AU - Gibas, A.

AU - Kilian, A.

AU - Bariletto, S.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Chronic hepatitis C (non-A, non-B hepatitis) is a common and often progressive viral liver disease. To assess the efficacy of therapy with the antiviral agent interferon alfa, we randomly assigned 166 patients with chronic hepatitis C to treatment with either 3 million or 1 million units of recombinant interferon alfa three times weekly for 24 weeks, or to no treatment. The probability of normalization or near normalization of the serum alanine aminotransferase levels after six months of interferon therapy was 46 percent in patients treated with 3 million units of interferon (p<0.001) and 28 percent in those treated with 1 million units (P<0.02), but only 8 percent in untreated patients. The serum alanine aminotransferase level became completely normal in 22 of the 26 patients (85 percent) who responded to treatment with 3 million units of interferon and 9 of the 16 patients (56 percent) who responded to treatment with 1 million units. The patients who received 3 million units of interferon had histologic improvement because of the regression of lobular and periportal inflammation. Relapse within six months after the completion of treatment occurred in 51 percent of the patients treated with 3 million units of interferon and 44 percent of those treated with 1 million units. We conclude that a 24-week course of interferon therapy is effective in controlling disease activity in many patients with hepatitis C, although relapse after the cessation of treatment is common.

AB - Chronic hepatitis C (non-A, non-B hepatitis) is a common and often progressive viral liver disease. To assess the efficacy of therapy with the antiviral agent interferon alfa, we randomly assigned 166 patients with chronic hepatitis C to treatment with either 3 million or 1 million units of recombinant interferon alfa three times weekly for 24 weeks, or to no treatment. The probability of normalization or near normalization of the serum alanine aminotransferase levels after six months of interferon therapy was 46 percent in patients treated with 3 million units of interferon (p<0.001) and 28 percent in those treated with 1 million units (P<0.02), but only 8 percent in untreated patients. The serum alanine aminotransferase level became completely normal in 22 of the 26 patients (85 percent) who responded to treatment with 3 million units of interferon and 9 of the 16 patients (56 percent) who responded to treatment with 1 million units. The patients who received 3 million units of interferon had histologic improvement because of the regression of lobular and periportal inflammation. Relapse within six months after the completion of treatment occurred in 51 percent of the patients treated with 3 million units of interferon and 44 percent of those treated with 1 million units. We conclude that a 24-week course of interferon therapy is effective in controlling disease activity in many patients with hepatitis C, although relapse after the cessation of treatment is common.

UR - http://www.scopus.com/inward/record.url?scp=0024368522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024368522&partnerID=8YFLogxK

M3 - Article

C2 - 2509916

AN - SCOPUS:0024368522

VL - 321

SP - 1501

EP - 1506

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 22

ER -